Fulcrum announces $100M stock offering and preliminary $202.9M cash position

Fulcrum Therapeutics, Inc.

Preliminary cash, cash equivalents, and marketable securities of ~$202.9M as of Dec 31, 2022.
Commenced underwritten public offering of $100M common stock, with 30-day option for additional $15M.
Terminated ATM equity distribution agreement with Piper Sandler effective Jan 17, 2023.
Goldman Sachs, SVB Securities, Piper Sandler joint book-runners; H.C. Wainwright lead manager.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.